Laboratoire d'Investigation Pré-clinique

LIP has developed a unique collection of 500 PDXs of different cancers (breast, lung, ovarian and prostate cancers; chordoma; uveal melanoma). All models are extensively characterised at the molecular level and in terms of drug response. We have also developed PDX, and organoids derived from patients with treatment-resistant breast and ovarian cancers. We bring our skills and knowledge to guide your projects, conducting extensive testing your products using our fully characterised models.